CMTM6/PD-L1在肝细胞癌中的表达及研究新进展

被引：0
作者：
何锋
孔盼盼
李鸣一
阿里米热·塔依尔
机构：
[1] 新疆医科大学附属肿瘤医院肝胆胰外科一病区
来源：
现代消化及介入诊疗 | 2024年 / 29卷 / 11期
关键词：
趋化素样超家族6; 肝细胞癌; 程序性死亡受体配体1;
D O I：
暂无
中图分类号：
R735.7 [肝肿瘤];
学科分类号：
100214 ;
摘要：
CMTM6作为CKLF-like MARVEL跨膜结构域家族的重要成员，近年来在肿瘤研究中取得了显著进展。研究表明CMTM6能够与程序性死亡受体配体1(PD-L1)结合，稳定癌细胞表面PD-L1的表达，还能够正向调控免疫共刺激因子CD58的表达，影响肿瘤中细胞免疫反应。此外，CMTM6还可以促进肿瘤相关巨噬细胞M2极化以及稳定波形蛋白，影响肿瘤微环境，促进肿瘤细胞的免疫逃逸。在这篇综述中，我们将简要介绍一下CMTM6与PD-L1在肝细胞癌中的表达及其研究进展。
引用
收藏
页码：1357 / 1361
页数：5
相关论文
共 35 条
[1]  
CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value.[J].Jie Wu;Lan Li;Siyi Wu;Bin Xu;.Cancer Biology & Medicine.2020, 03
[2]   趋化素样因子(CKLF1)对骨髓细胞增殖活性的研究 [J].
韩文玲 ;
芮珉 ;
张颖妹 ;
陈英玉 ;
钟英成 ;
狄春辉 ;
宋泉声 ;
马大龙 .
中国医学科学院学报, 2001, (02) :119-122
[3]  
Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma.[J].Jiahua Liang;Mingjian Ma;Wei Feng;Qiongcong Xu;Dong Chen;Jiaming Lai;Jiancong Chen.Apoptosis.2024, 1
[4]   New Advances in the Study of CMTM6, a Focus on Its Novel Non-Canonical Cellular Locations, and Functions beyond Its Role as a PD-L1 Stabilizer [J].
Urciaga-Gutierrez, Pedro Ivan ;
Franco-Topete, Ramon Antonio ;
Bastidas-Ramirez, Blanca Estela ;
Solorzano-Ibarra, Fabiola ;
Rojas-Diaz, Jose Manuel ;
Garcia-Barrientos, Nadia Tatiana ;
Klimov-Kravtchenko, Ksenia ;
Tellez-Banuelos, Martha Cecilia ;
Ortiz-Lazareno, Pablo Cesar ;
Peralta-Zaragoza, Oscar ;
Meneses-Acosta, Angelica ;
Alejandre-Gonzalez, Alan Guillermo ;
Bueno-Topete, Miriam Ruth ;
Haramati, Jesse ;
del Toro-Arreola, Susana .
CANCERS, 2024, 16 (18)
[5]  
Prognostic value of CMTM6 protein in hepatocellular carcinoma involving the regulation of the immune microenvironment..[J].Zhongheng Wei;Xuefeng Guo;Di Li;Jianchu Wang;Cheng Lin;Chao Tan;Yue Wang;Xiaonian Zhu;Shengkui Tan.International journal of biological macromolecules.2024, P2
[6]   Vimentin, inversely correlating with infiltration of CD8+T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma [J].
Liang, Yan ;
He, Shuo ;
Liu, Qing ;
Liu, Tao ;
Tan, Yiyi ;
Peng, Tianyuan ;
Huang, Conggai ;
Lu, Xiaomei ;
Zheng, Shutao .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2024, 1871 (07)
[7]   FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma [J].
Wang, Qingbin ;
Tan, Wenliang ;
Zhang, Ziyu ;
Chen, Qiuju ;
Xie, Zhiqin ;
Yang, Lei ;
Tang, Chenwei ;
Zhuang, Hongkai ;
Wang, Bingkun ;
Jiang, Jiahao ;
Ma, Xiaowu ;
Wang, Wentao ;
Hua, Yonglin ;
Shang, Changzhen ;
Chen, Yajin .
APOPTOSIS, 2024, 29 (9-10) :1529-1545
[8]   From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6 [J].
Melms, Johannes C. ;
Ho, Patricia ;
Rogava, Meri ;
Izar, Benjamin .
GENES AND IMMUNITY, 2024, 25 (01) :82-84
[9]  
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing..[J].Osman Köstek;Ahmet Demirel;Muhammet Bekir Hacıoğlu;Didem Tastekin;Senem Karabulut;Abidin Gündogdu;Nadiye Sever;Murat Ayhan;Abdussamed Çelebi;Nargiz Majidova;Alper Yaşar;Yeşim Ağyol;Pınar Erel;Erkam Kocaaslan;Ali Kaan Güren;Rukiye Arıkan;Selver Isık;Ozlem Ercelep;Sema Sezgin Goksu;Celal Alandag;İrem Bilgetekin;Burcu Caner;Ahmet Bilge Sahin;Ahmet Gulmez;Baran Akagunduz;Fatih Kose;Muhammet
[10]  
CMTM6 promotes hepatocellular carcinoma progression through stabilizing β-catenin..[J].Liu Qiyao;Wang Jiahui;Guo Zixia;Zhang Hanxiao;Zhou Yifan;Wang Pingzhang;Li Ting;Lu Wenping;Liu Fujun;Han Wenling.Cancer letters.2023,
1234